New drug hope for GPA patients with stubborn ENT symptoms
NCT ID NCT07176546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding TAVNEOS to standard treatment helps control ear, nose, and throat symptoms in people with granulomatosis with polyangiitis (GPA). About 30 adults with active ENT disease will receive either TAVNEOS or a placebo for 52 weeks. The goal is to see if more patients achieve full ENT remission without needing steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GPA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack Meridian School of Medicine - Advanced Lung and Airway Center
Edison, New Jersey, 08820, United States
-
Hospital for Special Surgery
New York, New York, 10021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to spot eye damage early in rare vasculitis patients
- Promising vasculitis drug trial halted early
- Experimental liquid drug tested in ventilator patients with rare lung bleeding disease
- New hope for Wegener's patients: drug aims to stop flare-ups
- New hope for rare vasculitis: Three-Drug trial targets Non-Responders
- Steroid showdown: can a tiny daily dose keep a rare disease at bay?